Tectonic Therapeutic

NASDAQ: TECX ↗$30.37 USD~$300M (post-IPO mid-cap, July 2026) MCAP

#Hereditary Hemorrhagic Telangiectasia (HHT)#Vascular Malformations #Cardiovascular Disease #GPCR-Targeted Antibodies #Conformationally-Stabilized Biologics

Tectonic Therapeutic is a clinical-stage biotechnology company developing a pipeline of conformationally-stabilized G-protein-coupled receptor (GPCR) antibodies and other biologics, with an initial focus on cardiovascular disease. Its lead program, TX000045, is being developed for Hereditary Hemorrhagic Telangiectasia (HHT) and other vascular malformations driven by abnormal TGF-beta signaling. The company's platform is designed to enable antibody-based targeting of GPCRs and other traditionally difficult targets.

Company Info

Sector:Biotechnology / Antibody Therapeutics (GPCR & Structural Biology)

Headquarters:Cambridge, Massachusetts, USA

Founded:2019

Website:www.tectonictx.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Q2 2026 financial results and TX000045 program update

Clinical Development Pipeline

TX000045

Target: Conformationally-stabilized antibody targeting a GPCR / TGF-beta co-receptor

Hereditary Hemorrhagic Telangiectasia (HHT) and other vascular malformations driven by aberrant TGF-beta signaling

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Aletta Schnitzler, Ph.D.

Co-Founder, President and Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Cambridge, MA

Apply Now →